הלוואות ואשראי לטווח ארוך של החברה: Clearmind Medicine (SPRC)

The price trajectory of SciSparc Ltd (SPRC) shown below correlates with the Israeli management's policy of cost minimization and profitability control amid typical small-cap risks, where long-term debt stands at 0.00. The business relies on the synergy of chemistry and cannabinoids to combat dementia and Tourette syndrome. The stability of raw material supplies for the CNS is ensured through a global supplier network and warehouse reserves.

Investors must assess an asset's capital stability by analyzing its liability structure. This indicator aggregates all loans with maturities exceeding one year, determining the level of long-term financial leverage. The trend in the company's long-term debt captures the trajectory of the debt load without market noise. For SciSparc Ltd (SPRC), low debt is critical when outsourcing R&D, as it ensures flexible patent scaling without excessive interest expenses.